Dr. Campbell joined Axial in 2016 and was appointed the company’s CEO in February 2021. Dr. Campbell has played a fundamental role in company’s growth and strategy over the last 4 years. He brings more than 25 years of experience leading and building teams that have strong track records of discovering and developing novel therapeutics for the patients who need them. Prior to joining Axial, Dr. Campbell held various leadership roles at biopharmaceutical and chemical manufacturing companies including Corden Pharma, Surface Logix and Insmed Inc. At Corden Pharma, Dr. Campbell served as Head of Product Management and Business Development for Carbohydrates and Lipids and as Head of Operations for Corden Pharma’s Woburn, MA manufacturing site. Prior to Corden Pharma Dr. Campbell served as Vice President of R&D at Ancora Pharmaceuticals, successfully triaging the company through the acquisition and integration process by Corden Pharma. While at Surface Logix and Insmed, Dr. Campbell played an integral role in the discovery and development of three clinical stage drug candidates, including the Rho kinase inhibitor belumosudil and TAK-607 (rIGF-1/BP-3). During his career Dr. Campbell has been co-inventor on nearly 20 issued patents.
He holds a BSc with Honors in Chemistry from St. Francis Xavier University, a Ph.D. in Organic Chemistry from the Queen’s University (Canada), and did post-doctoral research at Duke University.